Virus deactivation agent

Abstract

To provide a virus deactivation agent capable of deactivating virus present in an environment.SOLUTION: A virus deactivation agent includes 3-methyl-3-methoxybutanol and 2-ethylhexyl glyceryl ether as an active ingredient.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to a virus inactivating agent that inactivates viruses. [Background technology]

[0002] Viral infections are diseases that cause severe symptoms such as cold symptoms, pneumonia, hepatitis, and encephalitis, and are a perpetual threat to humanity. In recent years, influenza viruses have been raging worldwide, and sometimes pandemics have occurred due to the emergence of new influenza strains with altered antigenicity. In addition, in 2019, SARS coronavirus-2 (SARS-CoV-2) emerged and caused a pandemic, affecting not only life and health, but also economic activity and social functions.

[0003] In order to respond to such situations, vaccines and antiviral drugs are being developed, but the development of vaccines and treatments takes time and is not always successful. When a virus is brought into a living space by an infected person, the infection spreads directly from the patient or through the environment, including clothing, various instruments and materials, and equipment such as walls and air conditioners. Therefore, it is considered effective to prevent the spread of infection by removing or inactivating the virus by washing and disinfecting hands, clothing, and various instruments and materials to which the virus may adhere, as well as by inactivating the virus that has been splashed into the living space and that is floating in the air as an aerosol.

[0004] Conventionally, ethanol, sodium hypochlorite, chlorine dioxide, glutaraldehyde, etc. have been used for the purpose of inactivating viruses (for example, Patent Document 1). However, these common disinfectants are highly irritating to mucous membranes and skin, and their use is limited due to safety concerns. In addition, spraying chlorine dioxide has been devised as a method for chemically inactivating viruses present in air, but its effectiveness is not certain.

[0005] 3-Methyl-3-methoxybutanol is an alcohol-based solvent that is used in household products, printing, pesticides, automobiles, etc. 3-Methyl-3-methoxybutanol is also often used as a solvent for reed diffusers. In addition, 2-ethylhexyl glyceryl ether is highly compatible with various oily components, and is therefore used in detergents and cosmetics as a cleaning effect enhancer, solubilizer, thickener, etc. 2-Ethylhexyl glyceryl ether is known to have antibacterial properties against gram-positive bacteria and fungi. Patent Document 2 discloses a virus inactivating composition containing a glycol solvent and a nonionic surfactant such as an alkyl glyceryl ether surfactant, but does not report any effect on viruses by the combined use of 3-methyl-3-methoxybutanol and 2-ethylhexyl glyceryl ether. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Special Publication No. 4-502616 [Patent Document 2] Patent Publication No. 2022-26762 Summary of the Invention [Problem to be solved by the invention]

[0007] The present invention relates to providing a virus inactivating agent that is capable of inactivating viruses present in the environment. [Means for solving the problem]

[0008] The present inventors have found that a combination of 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether has a stronger virus inactivating effect than when either of them is used alone, and is therefore useful as a virus inactivating agent.

[0009] That is, the present invention relates to the following 1) and 2). 1) A virus inactivating agent whose active ingredients are 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether. 2) A method for inactivating a virus, comprising applying 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether, or a composition containing these, to an object for which there is a concern of viral contamination. Effect of the Invention

[0010] The virus inactivating agent of the present invention can inactivate viruses attached to hard or soft surfaces in the living environment, viruses splashed into living spaces, and viruses floating in the air as aerosols, thereby making it possible to prevent or reduce the spread of infection caused by those viruses. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] The 3-methyl-3-methoxybutanol of the present invention is also called 3-methoxy-3-methyl-1-butanol, and is a compound represented by the following chemical formula (CAS Registry Number: 56539-66-3).

[0012] [ka]

[0013] The 2-ethylhexyl glyceryl ether of the present invention is also called 3-(2-ethylhexyloxy)-1,2-propanediol or glycerin mono 2-ethylhexyl ether, and is an ether of glycerin and 2-ethylhexyl alcohol, and is a compound represented by the following chemical formula (CAS registration number: 70445-33-9).

[0014] [ka]

[0015] 3-Methyl-3-methoxybutanol and 2-ethylhexyl glyceryl ether can be purchased commercially. For example, they can be obtained from Fujifilm Wako Pure Chemical Industries, Tokyo Chemical Industry, etc. Alternatively, the same substances as the commercially available products or compositions containing them can be produced by chemical synthesis.

[0016] The 3-methyl-3-methoxybutanol and 2-ethylhexyl glyceryl ether of the present invention can be used in either liquid or gas phase, but from the standpoint of virus inactivation effect, it is preferable to use them in liquid phase.

[0017] Viruses that can be treated with the virus inactivating agent of the present invention include all kinds of viruses, regardless of the type of nucleic acid (RNA, DNA) and whether or not they have an envelope. Examples of enveloped viruses include influenza viruses, coronaviruses, SARS coronaviruses, SARS coronavirus-2, respiratory syncytial viruses, mumps viruses, Lassa viruses, dengue viruses, rubella viruses, and human immunodeficiency viruses, which have RNA as their nucleic acid, and human herpes viruses, vaccinia viruses, and hepatitis B viruses, which have DNA as their nucleic acid. In addition, examples of non-enveloped viruses include norovirus, poliovirus, echovirus, hepatitis A virus, hepatitis E virus, rhinovirus, astrovirus, rotavirus, coxsackievirus, enterovirus, and sapovirus, which have RNA as nucleic acid, and adenovirus, B19 virus, papovavirus, and human papillomavirus, which have DNA as nucleic acid.

[0018] Among these, preferred are enveloped viruses, more preferred are enveloped viruses having RNA as nucleic acid, and more preferred are influenza virus, human coronavirus, SARS coronavirus, and SARS coronavirus-2. SARS-coronavirus-2 (Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) is a SARS-related coronavirus that causes acute respiratory disease (COVID-19).

[0019] In the present invention, inactivation of a virus means the action of reducing or eliminating the activity of a virus and eliminating its infectivity to host cells. The virus inactivation effect can be confirmed, for example, by contacting a test sample with a virus, infecting a host cell with the virus, and measuring the virus infectivity. Here, the host cell may be any cell in which the target virus can grow, and for influenza virus, for example, canine kidney cells (MDCK), African green monkey kidney epithelial cells (Vero), and duck embryonic stem cell-derived cell line (EB66) can be used, and for human coronavirus, for example, human ileocecal adenocarcinoma cells (HCT-8), African green monkey kidney epithelial cells (VeroE6), and human liver cancer-derived cell line (Huh7) can be used.

[0020] As shown in the examples below, the combination of 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether exhibits an excellent virus inactivation effect against influenza viruses. Moreover, the effect is superior to the effect of 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether alone, and exceeds the additive effect when each is added alone, so it can be said to be a synergistic effect. On the other hand, no enhancement of the virus inactivation effect was observed by the combination of propylene glycol and 2-ethylhexylglyceryl ether. Therefore, the combination of 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether can be a virus inactivating agent, preferably a virus inactivating agent that inactivates viruses in a liquid phase. Alternatively, the combination of 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether can be used to manufacture a virus inactivating agent, preferably a virus inactivating agent that inactivates viruses in a liquid phase. Also, a combination of 3-methyl-3-methoxybutanol and 2-ethylhexyl glyceryl ether can be used to inactivate viruses, preferably in the liquid phase.

[0021] In the present invention, 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether may be applied in either order, or may be applied simultaneously. If the two agents are not applied simultaneously, the application interval between the two agents may be appropriately selected as long as the virus inactivation effect of 3-methyl-3-methoxybutanol or 2-ethylhexylglyceryl ether is enhanced. The agent comprising a combination of 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether may be a combination of 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether in a single formulation, or may be a kit in which the two are formulated separately and used simultaneously or separately at intervals. Among these, it is preferable to formulate 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether in a single formulation and apply them simultaneously.

[0022] The virus inactivating agent of the present invention may be in the form of a composition containing 3-methyl-3-methoxybutanol and 2-ethylhexyl glyceryl ether (for example, a virus inactivating composition, a hygiene product composition, etc.). That is, the virus inactivating agent of the present invention can be a virus inactivating composition or a hygiene product composition that exhibits a virus inactivating effect, or can be a material or preparation to be incorporated into these.

[0023] The virus inactivating compositions mentioned above include those used in a liquid or gas phase. The virus inactivating composition used in a liquid phase may contain, in addition to 3-methyl-3-methoxybutanol and 2-ethylhexyl glyceryl ether, antibacterial substances such as base, hypochlorous acid, hydrogen peroxide, and silver ion compounds, cationic antibacterial agents (benzethonium chloride, etc.), bactericides (triclosan, isopropyl methylphenol, etc.), surfactants, etc. The virus inactivating composition is prepared by appropriately blending additives such as chelating agents, moisturizing agents, lubricants, builders, buffers, abrasives, electrolytes, bleaching agents, fragrances, dyes, foam control agents, corrosion inhibitors, essential oils, thickeners, pigments, gloss enhancers, enzymes, detergents, solvents, dispersants, polymers, silicones, and hydrotropic substances. The form of such a composition may be, but is not limited to, a liquid, emulsion, cream, lotion, paste, gel, sheet (supported by base), oil, etc. The virus inactivating composition can be used by being appropriately blended with various cleaning agents (laundry cleaning agents, household cleaning agents, dishwashing cleaning agents, hair washing agents, hand washing agents, whole body cleaning agents, etc.), disinfectants, etc.

[0024] A virus inactivating composition used in a gas phase (e.g., a space virus inactivating composition) can be prepared by blending 3-methyl-3-methoxybutanol and 2-ethylhexyl glyceryl ether with a base and various additives (surfactants, UV absorbers, antioxidants, preservatives, deodorants, natural extracts, silicones, thickeners, dyes, pigments, coloring matter, oils, fragrances, etc.) The form of such a composition may be liquid or gel, etc., with a liquid being preferred.

[0025] In the present specification, the base may be oil-based or water-based, and may include conventionally known bases such as water, methanol, ethanol, propanol, isopropanol, butanol, isobutanol, propylene glycol, triethylene glycol, dimethyl ether, liquid propane, petrolatum, lanolin, castor oil, paraffinic hydrocarbons (e.g., liquid paraffin, etc.) These bases may be used alone or in combination of two or more. Examples of the fragrance include hydrocarbons, aldehydes, ketones, alcohols, phenols, lactones, esters, ethers, and thiols. When the virus inactivating composition is made into a gel preparation, it can be prepared by appropriately adding a natural or synthetic gelling agent, for example, a water-soluble gelling agent such as carrageenan or gellan gum, or an oil-soluble gelling agent such as metal soap or aluminum octylate, according to a conventionally known method.

[0026] Examples of the hygiene product compositions include lotions, creams, shampoos, hair conditioners, hand soaps, body shampoos, facial cleansers, bath additives, foams, antiperspirants, deodorants, anti-armpit odor agents, and oral hygiene products (mouthwashes, toothpastes, mouth fresheners, mouthwashes, etc.). The composition can be prepared by a conventional method by appropriately combining carriers acceptable for use as cosmetics, etc. (e.g., diluents, dispersants, buffers, pH adjusters, emulsifiers, surfactants, preservatives, stabilizers, antioxidants, colorants, moisturizers, thickeners, bactericides, fragrances, etc.).

[0027] In an embodiment in which the virus inactivating agent of the present invention is used as a composition, the content of the active ingredient can be appropriately determined depending on the form of the composition. From the viewpoint of virus inactivation, the content of 3-methyl-3-methoxybutanol relative to the total amount of the composition is preferably 5 v / v% or more, and more preferably 8 v / v% or more. From the viewpoint of virus inactivation, the content of 2-ethylhexyl glyceryl ether relative to the total amount of the composition is preferably 0.1 v / v % or more, and more preferably 0.2 v / v % or more.

[0028] In the present invention, from the viewpoint of virus inactivation, the ratio of the combination of 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether is preferably 10 parts by mass or more, more preferably 15 parts by mass or more, even more preferably 20 parts by mass or more of 3-methyl-3-methoxybutanol per part by mass of 2-ethylhexylglyceryl ether, and is preferably 200 parts by mass or less, more preferably 150 parts by mass or less, and even more preferably 100 parts by mass or less.

[0029] The virus inactivating agent of the present invention can inactivate viruses attached to the skin or mucous membrane of an animal contaminated with a virus, hard or soft surfaces of an inanimate object, waste, and other objects, or inactivate viruses splashed into a living space. Examples of the surface of an inanimate object include hard surfaces such as counters, sinks, restrooms, toilets, bathtubs, shower stands, floors, windows, doorknobs, walls, sewer outlets, pipes, and garbage collection areas in homes and business facilities; hard surfaces such as garbage inlets, work surfaces, and switch surfaces in special vehicles such as garbage trucks and sanitary vehicles; hard surfaces such as floors, handrails, and door surfaces in transportation vehicles such as railway cars and aircraft bodies; hard surfaces such as various instruments, tools, and miscellaneous goods such as kitchen utensils, furniture, telephones, and toys; and soft surfaces such as textile products (carpets, area rugs, curtains, seats, fabric furniture, clothing, and the like). Examples of waste include general waste (food residue, tissue paper, masks, and other household waste) and industrial waste (sludge, feces, medical waste, etc.). If the waste is contained in a bag, the surface of the bag may be targeted. Examples of living spaces include dining / kitchen rooms, bedrooms, children's rooms, bathrooms, toilets, and other areas of ordinary homes; facilities such as retail stores, restaurants, inns, hospitals, workshops, factories, and livestock farms; the inside of vehicles such as automobiles, trains, and airplanes; and semi-enclosed spaces (lockers, storerooms, closets, etc.; storage boxes (for toys, karaoke microphones, tableware, seasonings, writing utensils, and stationery)).

[0030] In the virus inactivating agent of the present invention, 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether, or a composition containing them, are applied to a target for which viral contamination is a concern, but the manner in which they are applied is not particularly limited, and 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether, or a composition containing them, may be brought into contact with or reacted with a virus in a liquid phase or gas phase. The method for contacting 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether with viruses in a liquid phase may be any of the following: applying 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether, or a composition containing these, directly to the target to be treated; spreading 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether, or a composition containing these, and sprinkling them on the target to be treated; or wiping the target surface with a sheet, gauze, towel, wet towel, tissue, wet tissue, or the like impregnated with 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether, or a composition containing these. In addition, 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether, or a composition containing them, is filled into a known spray container, such as a trigger spray container (direct pressure or pressure accumulation type), a dispenser type pump spray container, or an aerosol spray container equipped with a pressure-resistant container, and the spray amount is appropriately adjusted and sprayed onto the target to be treated. In addition, a method of filling into a spray device such as a pressurized air atomizing spray device, a nebulizer, or a diffuser, or a diffusion device such as a washer nozzle or a mist machine, and spraying into a space where viruses exist, is also included. By using it by dispersing it in a mist form into a space where viruses exist, the volatilization speed can be increased, and the virus inactivation effect can be rapidly exerted. In the present invention, from the viewpoint of appropriately delivering 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether, or a composition containing them, to a target where virus contamination is a concern, it is preferable to spray 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether, or a composition containing them in a non-heated state (non-heated state). When 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether, or a composition containing these, is sprayed in an unheated state onto a treatment target, the distance between the spraying part that sprays 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether, or a composition containing these, and the object is not particularly limited as long as it is within a range where the composition can be sprayed, but from the viewpoint of fully exerting the virus inactivation effect, the distance is preferably within 3 m, and more preferably within 1 m.

[0031] The average particle diameter of the spray particles is preferably 5 μm or more, more preferably 10 μm or more, and even more preferably 50 μm or more from the viewpoint of being less susceptible to the influence of air currents so that the spray can be sprayed at a targeted location, and from the viewpoint of spraying evenly while reducing the amount of 3-methyl-3-methoxybutanol and 2-ethylhexyl glyceryl ether or a composition containing them used and of facilitating volatilization and inactivating viruses in the space, the average particle diameter of the spray particles is preferably 500 μm or less, more preferably 200 μm or less, even more preferably 150 μm or less, and even more preferably 100 μm or less. Here, the average particle diameter of the spray particles is the volume-based median diameter (D50) measured by a laser diffraction particle analyzer, and can be measured by the method described in the Examples below.

[0032] As a method for contacting or reacting 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether, or a composition containing them, with viruses in the gas phase, for example, 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether are forcibly evaporated, which can inactivate viruses present in the living space and easily remove viruses from the space (virus removal). When 3-methyl-3-methoxybutanol and 2-ethylhexyl glyceryl ether are used after forced evaporation, such means may include, for example, a method of evaporating using a fan or the like, a heating and evaporation method using a heater or the like, and a method of evaporating using ultrasound. When performing spatial virus removal treatment, the amount of 3-methyl-3-methoxybutanol and 2-ethylhexyl glyceryl ether, or a composition containing them, used can be adjusted appropriately depending on the treatment mode, spatial environment such as temperature and humidity, etc. EXAMPLES

[0033] Test Example 1 Inactivation of influenza virus in liquid phase 1) Test virus Influenza A virus(H1N1,A / PR / 8 / 34)ATCC VR-1469

[0034] 2) Preparation of test virus solution MDCK cells were cultured at confluence (2 × 10 7 After washing with PBS, influenza A virus (H1N1, A / PR / 8 / 34) was added to 40 mL of serum free medium (Gibco, Hybridoma Serum Free Medium, P / N 123-00067, hereafter referred to as SFM) containing acetyl trypsin and gentamicin at a final concentration of 2 μg / mL, at an MOI of 0.001, to infect the cells. After culturing for about 48 hours at 37°C under 5% CO2, the cell culture supernatant was collected, centrifuged (800g / 10min at 4°C), the supernatant was centrifuged again (13,000g / 120min at 4°C), and the supernatant was removed to obtain a concentrated virus mass (precipitate). The concentrated virus mass was resuspended in SFM, and then centrifuged again (800g / 10min at 4°C), and the supernatant was collected to obtain an influenza A virus liquid. The virus titer of the influenza A virus solution was measured using the focus assay method, and based on the measurement results, it was determined to be 1.3 × 10 8 The virus titer was adjusted to FFU / mL to prepare the test virus solution.

[0035] 3) Preparation of test and control solutions The test solutions were prepared by thoroughly stirring 3-methyl-3-methoxybutanol (Kuraray), propylene glycol (Fujifilm Wako Pure Chemical Industries, Ltd.), and 2-ethylhexyl glyceryl ether (Fujifilm Wako Pure Chemical Industries, Ltd.) in a sterile tube so that the final concentration (v / v) when reacting with the virus was the concentration shown in Table 1. The test solution and distilled sterilized water (Invitrogen, P / N 10977) used as the control solution were dispensed in 45 μL aliquots into sterile tubes, and both were left to stand at room temperature until use in the test.

[0036] 4) Test operation (i) 5 μL of each test virus solution was added to 45 μL of the test solution or control solution, and the mixture was immediately stirred for 5 seconds using a vortex mixer and then allowed to stand. (ii) Five minutes after contact (addition of the test virus solution), the reaction was stopped by diluting the solution 20-fold with SFM and stirring it for 10 seconds with a vortex mixer. The solution was then serially diluted with SFM as appropriate. (iii) 500 μL of the diluted solution with SFM was inoculated onto confluent MDCK cells in a 12-well plate. (iv) After 18 to 22 hours, the infectious titer (FFU / mL) of the inoculated solution was measured (Focus assay).

[0037] 5) Calculation of Log reduction The log reduction shown in Table 1 was obtained by subtracting the logarithm of the infectious titer of the test solution from the logarithm of the infectious titer of the control solution.

[0038] [Table 1]

[0039] Test Example 2 Inactivation of influenza virus in liquid phase The influenza virus inactivation effect of test solutions prepared using 3-methyl-3-methoxybutanol (Kuraray), 2-ethylhexyl glyceryl ether (Kao), and fragrances (cis-3-hexenyl formate (Sigma-Aldrich), hexyl acetate (Fujifilm Wako Pure Chemical Industries, Ltd.)) at final concentrations (v / v) as shown in Table 2 below was evaluated in the same manner as described in Test Example 1.

[0040] [Table 2]

[0041] As shown in Tables 1 and 2, the combined use of 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether showed a superior virus inactivation effect compared to the use of either compound alone. The log reduction when 3-methyl-3-methoxybutanol and 2-ethylhexylglyceryl ether were added in combination was greater than the activity value obtained by adding the activities of either compound alone, indicating that the combination had a synergistic effect on virus inactivation. On the other hand, the log reduction when propylene glycol and 2-ethylhexylglyceryl ether were added in combination was smaller than the activity value obtained by adding the activities of either compound alone, indicating that the combination of propylene glycol and 2-ethylhexylglyceryl ether did not enhance the virus inactivation effect.

[0042] Test Example 3 Inactivation of influenza virus in a spray form A virus inactivation test was carried out in a 36 L acrylic container (product name: AS ONE Suction Box 10 L 350 x 490 x 240 mm). 8 The concentration of 100% (FFU / mL) was sprayed using a compressor-type nebulizer (NE-C803, manufactured by Omron). A test liquid with the composition shown in Example 14 in Table 2 was prepared and sprayed into an acrylic container through a hole in the center of the lid using a sprayer. A Koshin Mister Auto 2.5L sprayer was used (maximum pressure approximately 0.3 MPa), and the tip nozzle was changed to a fine mist nozzle (Ikeuchi Kiri, hollow cone nozzle KB8010N). As a control, an evaluation was performed under conditions where the test liquid was not sprayed. Specifically, the test liquid and the test virus liquid were simultaneously sprayed in an acrylic box for 10 seconds and then left standing for 10 seconds. The virus floating in the container space was collected into a total of 3 mL of SFM in a bubbler (manufactured by Shibata Scientific Technology) using an aspirator for 3 minutes. The virus that had fallen onto two 6-cm-diameter dishes (manufactured by AGC Techno Glass) previously placed on the bottom surface of the acrylic container 3 minutes and 20 seconds after the start of the test was collected with 1.5 mL of SFM per dish, and the total was made 3 mL. After diluting the collected virus solution, it was inoculated onto MDCK cells (derived from canine renal tubular epithelial cells) that had been cultured in a 12-well plate in advance, and after culturing under conditions of 37°C and 5% CO2 for about 18 hours, the number of foci formed was measured, and the virus infectivity titer was measured. By subtracting the logarithm value of the infectivity titer of the test liquid from the logarithm value of the infectivity titer of the control, the log reduction amount shown in Table 3 was obtained.

[0043]

Table 3

[0044] As shown in Table 3, by spraying the test liquid having the composition shown in Example 14, a virus inactivating effect was exhibited against both the floating virus and the falling virus in the space. Also, when the median diameter (D50) on a volume basis of the spray of the test liquid having the composition shown in Example 14 was measured according to the following conditions, it was 59.3 μm. <Measurement conditions for D50> Laser diffraction particle size distribution measuring device (manufacturer: Spraytec manufactured by Malvern), using lens 300 mm Spraying direction: Spray horizontally Measurement area: The measuring device was arranged so that the point 15 cm horizontally (spraying direction) from the spray outlet of the sprayer became the measurement area. Sampling time: 1 s In addition, in the same manner as above, test liquids having the compositions shown in Examples 6 and 11 of Table 2 were prepared, and when the median diameter (D50) on a volume basis when sprayed with a sprayer was measured, it was 59.1 μm for Example 6 and 58.8 μm for Example 11.

[0045] Test Example 4: Inactivation of SARS-CoV-2 SARS-CoV-2 hCoV-19 / Japan / TY11-927 / 2021 was used as the test virus strain. A model contaminant nutrient medium (Difco) was added to the virus solution so that the final concentration during the reaction was 1.5% (v / v). The reaction was carried out by adding 3 μL of the virus solution to 27 μL of the test solution having the composition shown in Example 14 of Table 2 and mixing. The reaction was carried out at room temperature for 5 minutes, and after 5 minutes, the solution was diluted 20-fold using a cell maintenance medium (Dulbecco's modified Eagle medium (Nacalai Tesque, Inc.) with 2% fetal bovine serum, 100 U / mL penicillin, 100 μg / mL streptomycin, and 1 mg / mL geneticin G418) and serially diluted 3-fold using the cell maintenance medium. VeroE6 / TMPRSS2 cells that had been cultured in advance in a 96-well plate were inoculated with 100 μL of the diluted reaction solution per well and infected for approximately 1 hour at 37°C and 5% CO2. After infection, all of the dilution solution was removed, the cells were washed twice with cell maintenance medium, and new cell maintenance medium was added and cultured for 3 days. After culture, the presence or absence of morphological changes in the cells (cytopathic effect: CPE) was observed using an inverted phase contrast microscope, and the 50% tissue culture infectious dose (TCID 50 The infectivity of the reaction solution was calculated using the TCID 50 The TCID was calculated and the test was repeated in duplicate to confirm the consistency of the results for each test condition. 50 was calculated and it was confirmed that the results of the two measurements were consistent. Virus inactivation effect (log reduction value) = logTCID of control 50 / mL-logTCID of reaction solution 50 / mL

[0046] The test solution having the composition shown in Example 14 showed a virus inactivation effect of 3.1 log or more against SARS-CoV-2.

Claims

1. A virus inactivator comprising 3-methyl-3-methoxybutanol and 2-ethylhexyl glyceryl ether as active ingredients.

2. The virus inactivator according to Claim 1, wherein the virus is an RNA virus having an envelope.

3. The virus inactivator according to Claim 1, wherein the virus is an influenza virus.

4. The virus inactivator according to any one of Claims 1 to 3, which inactivates the virus in a liquid phase.

5. A virus inactivating composition containing 8% (v / v) or more of 3-methyl-3-methoxybutanol and 0.2% (v / v) or more of 2-ethylhexyl glyceryl ether.

6. A virus inactivating composition containing 3-methyl-3-methoxybutanol and 2-ethylhexyl glyceryl ether, wherein the content of 3-methyl-3-methoxybutanol is 10 parts by mass or more and 200 parts by mass or less with respect to 1 part by mass of 2-ethylhexyl glyceryl ether.

7. A virus inactivating method of applying 3-methyl-3-methoxybutanol and 2-ethylhexyl glyceryl ether, or a composition containing these, to an object suspected of being contaminated with a virus.

8. The virus inactivating method according to Claim 7, wherein the application form is a form of spraying using a sprayer selected from any one of a pressurized air atomizing spray device, an atomizing device, and a diffusing device, and the average particle diameter of the spray particles at a point 15 cm in the spray direction from the spray outlet of the sprayer is 5 μm or more and 500 μm or less.